[Clinical evaluation of a new oral cephem, cefpodoxime proxetil in children].
Cefpodoxime proxetil (CPDX-PR, CS-807) was evaluated for its efficacy, safety and pharmacokinetics in children. CPDX-PR was effective in 93.6% of 47 cases with respiratory tract, middle ear, skin or urinary tract infections. Twice or 3 times daily administration of 3 mg/kg each was sufficient to treat streptococcal pharyngitis and Haemophilus influenzae infections. No severe adverse reaction was encountered in 52 cases treated with CPDX-PR. The serum half-life was approximately 2.17 +/- 0.24 hours after oral administration.
Meguro
H
H
Department of Pediatrics, School of Medicine, Teikyo University.
Arimasu
O
O
Shiraishi
H
H
Tajima
T
T
Hiruma
F
F
Nishimura
S
S
Sugie
N
N
Sugamata
K
K
Abe
T
T
Fujii
R
R
D000284:Administration, Oral; D001424:Bacterial Infections / Q000188:drug therapy* / Q000378:metabolism / Q000382:microbiology; D015296:Ceftizoxime / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D055598:Chemical Phenomena; D002621:Chemistry; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D005260:Female; D006207:Half-Life; D006801:Humans; D007223:Infant; D008297:Male; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000378:metabolism / Q000382:microbiology; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000378:metabolism / Q000382:microbiology; D000097627:Cefpodoxime Proxetil
D015296:Ceftizoxime; D000097627:Cefpodoxime Proxetil